BACKGROUND: Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of atypical hemolytic uremic syndrome linked to complement alternative pathway dysregulation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We sought to retrospectively analyze the presentation, outcome, and frequency of complement alternative pathway gene variants in a larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-associated hemolytic uremic syndrome. RESULTS: Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and in the postpartum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six (78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions, and four (5%) received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients reached ESRD, 15 (19%) had CKD, and 18 (28%) patients experienced hemolytic uremic syndrome relapse. Twenty-four patients (27%) received a kidney transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) patients. Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) and CFI genes (9%). CONCLUSIONS: Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic uremic syndrome nonrelated to pregnancy have the same severity at onset and during follow-up and the same frequency of complement gene variants.
BACKGROUND: Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of atypical hemolytic uremic syndrome linked to complement alternative pathway dysregulation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We sought to retrospectively analyze the presentation, outcome, and frequency of complement alternative pathway gene variants in a larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-associated hemolytic uremic syndrome. RESULTS: Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and in the postpartum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six (78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions, and four (5%) received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients reached ESRD, 15 (19%) had CKD, and 18 (28%) patients experienced hemolytic uremic syndrome relapse. Twenty-four patients (27%) received a kidney transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) patients. Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) and CFI genes (9%). CONCLUSIONS: Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic uremic syndrome nonrelated to pregnancy have the same severity at onset and during follow-up and the same frequency of complement gene variants.
Authors: Anna Richards; M Kathryn Liszewski; David Kavanagh; Celia J Fang; Elizabeth Moulton; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Marina Noris; Timothy H J Goodship; John P Atkinson Journal: Mol Immunol Date: 2006-08-01 Impact factor: 4.407
Authors: David Kavanagh; Elizabeth J Kemp; Elizabeth Mayland; Robin J Winney; Jeremy S Duffield; Graham Warwick; Anna Richards; Roy Ward; Judith A Goodship; Timothy H J Goodship Journal: J Am Soc Nephrol Date: 2005-05-25 Impact factor: 10.121
Authors: Patrick J Gleeson; Valerie Wilson; Thomas E Cox; Seema D Sharma; Kate Smith-Jackson; Lisa Strain; David Lappin; Teresa McHale; David Kavanagh; Timothy H J Goodship Journal: Immunobiology Date: 2016-05-10 Impact factor: 3.144
Authors: Yi Yu; Michael P Triebwasser; Edwin K S Wong; Elizabeth C Schramm; Brett Thomas; Robyn Reynolds; Elaine R Mardis; John P Atkinson; Mark Daly; Soumya Raychaudhuri; David Kavanagh; Johanna M Seddon Journal: Hum Mol Genet Date: 2014-05-20 Impact factor: 6.150
Authors: Hugh P Morgan; Christoph Q Schmidt; Mara Guariento; Bärbel S Blaum; Dominic Gillespie; Andrew P Herbert; David Kavanagh; Haydyn D T Mertens; Dmitri I Svergun; Conny M Johansson; Dušan Uhrín; Paul N Barlow; Jonathan P Hannan Journal: Nat Struct Mol Biol Date: 2011-02-13 Impact factor: 15.369
Authors: Viviana P Ferreira; Andrew P Herbert; Claudio Cortés; Kristi A McKee; Bärbel S Blaum; Stefan T Esswein; Dusan Uhrín; Paul N Barlow; Michael K Pangburn; David Kavanagh Journal: J Immunol Date: 2009-06-01 Impact factor: 5.422
Authors: David Kavanagh; Anna Richards; Marina Noris; Richard Hauhart; M Kathryn Liszewski; Diana Karpman; Judith A Goodship; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Timothy H J Goodship; John P Atkinson Journal: Mol Immunol Date: 2007-06-26 Impact factor: 4.407